José Baselga Selected Research

NVP-BKM120

11/2018	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
11/2017	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
1/2017	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
11/2012	Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
11/2012	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
1/2012	Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José Baselga Research Topics

Disease

139	Neoplasms (Cancer) 04/2021 - 01/2002
129	Breast Neoplasms (Breast Cancer) 11/2021 - 02/2002
21	Disease Progression 01/2020 - 01/2002
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 07/2002
12	Pathologic Complete Response 01/2019 - 12/2005
11	Diarrhea 01/2020 - 01/2012
10	Neoplasm Metastasis (Metastasis) 01/2016 - 02/2002
9	Triple Negative Breast Neoplasms 01/2019 - 03/2010
8	Exanthema (Rash) 01/2020 - 08/2005
6	Hyperglycemia 01/2020 - 04/2008
6	Carcinoma (Carcinomatosis) 01/2017 - 08/2002
6	Colorectal Neoplasms (Colorectal Cancer) 12/2015 - 06/2005
5	Neutropenia 10/2017 - 04/2008
5	Stomatitis 01/2017 - 04/2008
5	Squamous Cell Carcinoma of Head and Neck 01/2017 - 08/2005
3	Cardiotoxicity 04/2018 - 01/2009
3	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 01/2015
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2017 - 06/2015
3	Carcinogenesis 03/2016 - 10/2004
3	Lung Neoplasms (Lung Cancer) 10/2011 - 07/2002
3	Adenocarcinoma 12/2010 - 11/2005
2	Melanoma (Melanoma, Malignant) 01/2020 - 08/2015
2	Vomiting 01/2019 - 11/2012
2	Heart Failure 01/2019 - 01/2006
2	Fatigue 01/2019 - 02/2012

Drug/Important Bio-Agent (IBA)

51	Trastuzumab (Herceptin)FDA Link 01/2021 - 10/2004
41	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2002
31	human ERBB2 proteinIBA 01/2020 - 04/2005
25	Lapatinib (GW572016)FDA Link 01/2019 - 04/2007
22	Phosphotransferases (Kinase)IBA 04/2021 - 08/2004
22	Hormones (Hormone)IBA 01/2019 - 02/2002
21	Estrogen ReceptorsIBA 10/2020 - 12/2005
18	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2006
16	pertuzumabIBA 01/2021 - 03/2010
14	Monoclonal AntibodiesIBA 09/2017 - 01/2004
13	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2002
13	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 08/2002
13	Everolimus FDA Link 01/2019 - 04/2008
11	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 07/2013
10	Aromatase InhibitorsIBA 10/2020 - 02/2012
10	Cetuximab (Erbitux)FDA Link 01/2016 - 10/2004
10	Docetaxel (Taxotere)FDA Link 02/2015 - 02/2008
10	Tyrosine Kinase InhibitorsIBA 11/2014 - 06/2003
9	Fulvestrant (Faslodex)FDA Link 04/2021 - 04/2015
9	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2004
9	exemestane (Aromasin)FDA Link 01/2019 - 02/2012
9	Capecitabine (Xeloda)FDA Link 12/2017 - 10/2004
9	Pharmaceutical PreparationsIBA 07/2017 - 03/2010
9	Biological ProductsIBA 01/2017 - 08/2005
9	Gefitinib (Iressa)FDA Link 09/2006 - 01/2002
8	Mitogen-Activated Protein KinasesIBA 10/2018 - 10/2004
8	Epidermal Growth Factor (EGF)IBA 11/2017 - 10/2004
7	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2019 - 08/2007
7	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2011 - 04/2005
6	taxaneIBA 01/2020 - 08/2007
6	AlpelisibIBA 01/2019 - 07/2013
6	NVP-BKM120IBA 11/2018 - 01/2012
6	Estrogens (Estrogen)FDA Link 12/2017 - 09/2008
6	TOR Serine-Threonine KinasesIBA 10/2017 - 04/2008
6	Fluorouracil (Carac)FDA LinkGeneric 02/2017 - 10/2004
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 05/2013 - 01/2002
5	Phenobarbital (Luminal)FDA Link 01/2020 - 03/2010
5	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019 - 11/2012
5	LigandsIBA 01/2019 - 12/2010
5	ipatasertibIBA 10/2017 - 12/2013
5	Mechanistic Target of Rapamycin Complex 1IBA 01/2017 - 05/2012
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2016 - 06/2013
4	capivasertibIBA 04/2021 - 07/2017
4	2- (3- (2- (1- isopropyl- 3- methyl- 1H- 1,2- 4- triazol- 5- yl)- 5,6- dihydrobenzo(f)imidazo(1,2- d)(1,4)oxazepin- 9- yl)- 1H- pyrazol- 1- yl)- 2- methylpropanamideIBA 01/2019 - 04/2016
4	PlatinumIBA 01/2019 - 08/2005
4	Sorafenib (BAY 43-9006)FDA Link 12/2017 - 05/2012
4	dalotuzumabIBA 10/2017 - 10/2011
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2017 - 12/2005
4	ParaffinIBA 01/2017 - 04/2007
4	RNA (Ribonucleic Acid)IBA 03/2016 - 09/2011
4	AntibodiesIBA 03/2014 - 07/2006
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014 - 12/2005
4	Growth Factor ReceptorsIBA 10/2007 - 01/2004
3	Cell-Free Nucleic AcidsIBA 01/2021 - 10/2016
3	neratinibIBA 01/2020 - 11/2014
3	VemurafenibIBA 01/2020 - 08/2015
3	olaparibIBA 12/2018 - 11/2012
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2018 - 01/2017
3	ridaforolimusIBA 10/2017 - 01/2015
3	Drug CombinationsIBA 08/2017 - 02/2015
3	Formaldehyde (Formol)FDA Link 01/2017 - 01/2014
3	Ado-Trastuzumab EmtansineIBA 01/2017 - 11/2012
3	Methotrexate (Mexate)FDA LinkGeneric 01/2014 - 12/2005
2	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 04/2021 - 01/2016
2	ChromatinIBA 10/2020 - 01/2017
2	MicroRNAs (MicroRNA)IBA 02/2020 - 01/2019
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2019 - 12/2017
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2019 - 01/2016
2	Letrozole (Femara)FDA LinkGeneric 01/2019 - 06/2009
2	antineoplaston A10 (A 10)IBA 01/2019 - 11/2012

Therapy/Procedure

99	Therapeutics 01/2021 - 01/2002
22	Drug Therapy (Chemotherapy) 01/2021 - 01/2004
9	Neoadjuvant Therapy 02/2020 - 02/2009
5	Aftercare (After-Treatment) 01/2019 - 06/2007
3	Radiotherapy 01/2016 - 01/2004